1 | ( L ) ASCORBATO DI CALCIO | 1件: Calcium Calcium | - | - | - | 2件: 96 96, 97 |
2 | (+) erythromefloquine | - | - | - | - | 1件: 46 46 |
3 | (+) isomer of racemic mefloquine | 1件: Mefloquine Mefloquine | 1件: D04895
D04895
| - | - | 1件: 46 46 |
4 | (+) isomer or racemic mefloquine | 1件: Mefloquine Mefloquine | 1件: D04895
D04895
| - | - | 1件: 46 46 |
5 | (+)- Epicatechin | 1件: Epicatechin Epicatechin | - | - | - | 1件: 113 113 |
6 | (+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid | 2件: Naproxen Naproxen, Propanoic acid | 2件: D00118
D00118
,
D02310
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 |
7 | (+)-Epicatechin | 1件: Epicatechin Epicatechin | - | - | - | 1件: 113 113 |
8 | (+)erythromefloquine | - | - | - | - | 1件: 46 46 |
9 | (-)-3-(4-Aminophenyl)-2-methoxypropionic acid | - | - | - | - | 1件: 97 97 |
10 | (-)-Epicatechin | 1件: Epicatechin Epicatechin | - | - | - | 2件: 86 86, 113 |
11 | (-)-trans-delta-9-Tetrahydrocannabinol | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
12 | (1-3)-beta-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 |
13 | (1-3)-ß-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 |
14 | (11C)PE2I | - | - | - | - | 1件: 6 6 |
15 | (18)F-FDG | - | - | - | - | 1件: 85 85 |
16 | (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide | - | - | - | - | 1件: 11 11 |
17 | (2)-epigallocatechin-3-gallate (EGCG) | 2件: Epigallocatechin Epigallocatechin, Epigallocatechin gallate | - | - | - | 1件: 8 8 |
18 | (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) | - | - | - | - | 1件: 6 6 |
19 | (2R)-2-Propyloctanoic acid | 1件: Arundic acid Arundic acid | 1件: D06296
D06296
| - | - | 1件: 2 2 |
20 | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide | - | - | - | - | 1件: 309 309 |
21 | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide | - | - | - | - | 1件: 309 309 |
22 | (3beta, 5beta, 25R)-spirostan-3-ol | - | - | - | - | 1件: 6 6 |
23 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 |
24 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 |
25 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 |
26 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 |
27 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 |
28 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 |
29 | (3ß, 5ß, 25R)-spirostan-3-ol | - | - | - | - | 1件: 6 6 |
30 | (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile | - | - | - | - | 1件: 231 231 |
31 | (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’- | - | - | - | - | 1件: 79 79 |
32 | (6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate | - | - | - | - | 1件: 2 2 |
33 | (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol | - | - | - | - | 1件: 6 6 |
34 | (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine | - | - | - | - | 1件: 301 301 |
35 | (CDP6038 | - | - | - | - | 1件: 46 46 |
36 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime | - | - | - | - | 1件: 161 161 |
37 | (IM) AVONEX® | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
38 | (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate | - | - | - | - | 1件: 6 6 |
39 | (Pyr1)apelin-13 | - | - | - | - | 1件: 86 86 |
40 | (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide | - | - | - | - | 1件: 13 13 |
41 | (R)-(-)-2-Propyloctaroic acid | - | - | - | - | 1件: 2 2 |
42 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4- | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 |
43 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 |
44 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 |
45 | (R)-3-(1-oxo-propoxy)-4-(N,N,N-trimethyl amonium chloride)-butanoic acid | 2件: Butyric Acid Butyric Acid, Chloride ion | 1件: D05866
D05866
| - | - | 1件: 97 97 |
46 | (R)-[N-metil-11C1-PK11195(PK) | - | - | - | - | 1件: 127 127 |
47 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 |
48 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 |
49 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1HPYRAZOLE-4-CARBOXAMIDE | - | - | - | - | 1件: 58 58 |
50 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate | 1件: Piperazine Piperazine | 6件: D00807
D00807
,
D01393
,
D02127
,
D02145
,
D05486
,
D06224
| - | - | 1件: 272 272 |
51 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate | 1件: Piperazine Piperazine | 6件: D00807
D00807
,
D01393
,
D02127
,
D02145
,
D05486
,
D06224
| - | - | 1件: 272 272 |
52 | (R)-troloxamide quinone | - | - | - | - | 1件: 6 6 |
53 | (RS)-baclofen | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 10 10 |
54 | (RS)-baclofen, naltrexone hydrochloride and D-sorbitol | 3件: Baclofen Baclofen, Naltrexone, Sorbitol | 4件: D00096
D00096
,
D00241
,
D02095
,
D05113
| 5件: GABBR1 GABBR1, GABBR2, OPRD1, OPRK1, OPRM1 💬 | 9件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 10 10 |
55 | (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol | - | - | - | - | 1件: 6 6 |
56 | (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate | - | - | - | - | 1件: 6 6 |
57 | (S)-(-)-3-(4-Aminophenyl)-2-methoxypropionic Acid | - | - | - | - | 1件: 97 97 |
58 | (S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid | - | - | - | - | 1件: 86 86 |
59 | (S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one | - | - | - | - | 1件: 240 240 |
60 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 |
61 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 |
62 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo | - | - | - | - | 1件: 284 284 |
63 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: D00731
D00731
| - | - | 1件: 284 284 |
64 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m | - | - | - | - | 1件: 284 284 |
65 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: D00731
D00731
| - | - | 1件: 284 284 |
66 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5- yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 |
67 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxyben | - | - | - | - | 1件: 97 97 |
68 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 |
69 | * D.3.4 Solution for infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 |
70 | * D.3.4 Solution for injection in pre-filled syringe | - | - | - | - | 1件: 97 97 |
71 | * D.3.4 Solution for injection/infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 |
72 | * D.3.6.2.1 - valore : Every 4 weeks dosing of 200 mg | - | - | - | - | 1件: 41 41 |
73 | * D.3.6.2.1 - valore :Every 4 weeks dosing of 400 mg | - | - | - | - | 1件: 41 41 |
74 | **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter. | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
75 | -aminosalicylic acid | 1件: Aminosalicylic acid Aminosalicylic acid | 1件: D00162
D00162
| - | - | 2件: 96 96, 97 |
76 | 0 mg Prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 44 44 |
77 | 0 mg tropicamide | 1件: Tropicamide Tropicamide | 1件: D00397
D00397
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 |
78 | 0,25 mg RPC1063 | - | - | - | - | 1件: 96 96 |
79 | 0,5 mg Fingolimod | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
80 | 0,5 mg Prevenar i.m. | - | - | - | - | 1件: 51 51 |
81 | 0,5 mg seasonal influenza vaccine i.m. | - | - | - | - | 1件: 51 51 |
82 | 0.005% Lacripep | - | - | - | - | 1件: 53 53 |
83 | 0.01% Lacripep | - | - | - | - | 1件: 53 53 |
84 | 0.02% Fm, SH | - | - | - | - | 1件: 53 53 |
85 | 0.02% Fm, SH, 0.05% CsA | - | - | - | - | 1件: 53 53 |
86 | 0.02% Fm, SH, AS | - | - | - | - | 1件: 53 53 |
87 | 0.04 mg Lu AE04621 | - | - | - | - | 1件: 6 6 |
88 | 0.05%cyclosporin eye drop | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 38 38 |
89 | 0.08 mg Lu AE04621 | - | - | - | - | 1件: 6 6 |
90 | 0.12% saline | - | - | - | - | 1件: 299 299 |
91 | 0.15mg KPG-818 dose | - | - | - | - | 1件: 49 49 |
92 | 0.2 mg Lu AE04621 | - | - | - | - | 1件: 6 6 |
93 | 0.25 mg RPC103 | - | - | - | - | 1件: 97 97 |
94 | 0.25 mg RPC1063 | - | - | - | - | 3件: 13 13, 96, 97 |
95 | 0.25mg RPC103 | - | - | - | - | 1件: 97 97 |
96 | 0.25mg RPC1063 | - | - | - | - | 2件: 13 13, 97 |
97 | 0.3 mg tropicamide | 1件: Tropicamide Tropicamide | 1件: D00397
D00397
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 |
98 | 0.4 mg Lu AE04621 | - | - | - | - | 1件: 6 6 |
99 | 0.4mL prefilled syringes | - | - | - | - | 1件: 107 107 |
100 | 0.5 mg budesonide effervescent tablet for orodispersible use | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
101 | 0.5 mg RPC1063 | - | - | - | - | 2件: 13 13, 97 |
102 | 0.5% marcaine | - | - | - | - | 1件: 70 70 |
103 | 0.5mg RPC1063 | - | - | - | - | 1件: 13 13 |
104 | 0.6 mg Lu AE04621 | - | - | - | - | 1件: 6 6 |
105 | 0.6mg KPG-818 dose | - | - | - | - | 1件: 49 49 |
106 | 0.7mL prefilled syringes | - | - | - | - | 1件: 107 107 |
107 | 0.8 mg Lu AE04621 | - | - | - | - | 1件: 6 6 |
108 | 0.9% Isotonic Saline (IS) | - | - | - | - | 1件: 299 299 |
109 | 0.9% Isotonic Saline (IS), 4mL | - | - | - | - | 1件: 299 299 |
110 | 0.9% normal saline (control) | - | - | - | - | 1件: 299 299 |
111 | 0.9% physiological saline | - | - | - | - | 1件: 266 266 |
112 | 0.9% saline | - | - | - | - | 2件: 6 6, 70 |
113 | 0.9% sodium chloride | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 4件: 6 6, 14, 51, 53 |
114 | 0.9% sodium chloride (normal saline) | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 1件: 6 6 |
115 | 0.9% Sodium Chloride Injection | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 1件: 168 168 |
116 | 0.9% w/v isotonic sodium chloride solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 1件: 50 50 |
117 | 0.9% w/v sodium chloride solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 1件: 299 299 |
118 | 0000 | - | - | - | - | 1件: 3 3 |
119 | 00000 | - | - | - | - | 2件: 6 6, 96 |
120 | 000000 | - | - | - | - | 1件: 6 6 |
121 | 000000000 | - | - | - | - | 1件: 66 66 |
122 | 0002-8971 | - | - | - | - | 1件: 70 70 |
123 | 00070500 | - | - | - | - | 1件: 60 60 |
124 | 00201600 | - | - | - | - | 1件: 229 229 |
125 | 00244301 | - | - | - | - | 1件: 274 274 |
126 | 00258901 | - | - | - | - | 1件: 85 85 |
127 | 00305800 | - | - | - | - | 2件: 53 53, 160 |
128 | 00319301 | - | - | - | - | 1件: 60 60 |
129 | 00322900 | - | - | - | - | 1件: 85 85 |
130 | 009-0 | - | - | - | - | 1件: 6 6 |
131 | 009-1 | - | - | - | - | 1件: 6 6 |
132 | 009-2 | - | - | - | - | 1件: 6 6 |
133 | 009-3 | - | - | - | - | 1件: 6 6 |
134 | 009-4 | - | - | - | - | 1件: 6 6 |
135 | 009-5 | - | - | - | - | 1件: 6 6 |
136 | 009-A0 | - | - | - | - | 1件: 6 6 |
137 | 009-A1 | - | - | - | - | 1件: 6 6 |
138 | 009-A2 | - | - | - | - | 1件: 6 6 |
139 | 009-A3 | - | - | - | - | 1件: 6 6 |
140 | 0109-0012A 100 mg/ml | - | - | - | - | 1件: 46 46 |
141 | 0109-0012A 25 mg/ml | - | - | - | - | 1件: 46 46 |
142 | 0109-0012A 50 mg/ml | - | - | - | - | 1件: 46 46 |
143 | 0114-0006B | - | - | - | - | 2件: 46 46, 96 |
144 | 023145028 | - | - | - | - | 1件: 6 6 |
145 | 032166011 | - | - | - | - | 1件: 13 13 |
146 | 033283045 | - | - | - | - | 1件: 13 13 |
147 | 033841 | - | - | - | - | 1件: 299 299 |
148 | 034091165 | - | - | - | - | 1件: 13 13 |
149 | 035418060 | - | - | - | - | 1件: 13 13 |
150 | 043906039 | - | - | - | - | 1件: 6 6 |
151 | 045251016 | - | - | - | - | 1件: 19 19 |
152 | 0881 | - | - | - | - | 2件: 46 46, 271 |
153 | 0C23 | - | - | - | - | 1件: 67 67 |
154 | 1 - Andrographis paniculata p/st extract | - | - | - | - | 1件: 13 13 |
155 | 1 mg budesonide effervescent tablet for orodispersible use | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
156 | 1 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
157 | 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
158 | 1 mg RPC1063 | - | - | - | - | 2件: 13 13, 97 |
159 | 1 mg tropicamide | 1件: Tropicamide Tropicamide | 1件: D00397
D00397
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 |
160 | 1 mg/kg CNTO 136 | - | - | - | - | 1件: 49 49 |
161 | 1 ml 0.9 % NaCl | - | - | - | - | 1件: 46 46 |
162 | 1% lignocaine | 1件: Lidocaine Lidocaine | 3件: D00358
D00358
,
D02086
,
D08127
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 84 84 |
163 | 1% Steroid Cream | - | - | - | - | 1件: 13 13 |
164 | 1) Inosine 5'-monophosphate | 1件: Inosine Inosine | 1件: D00054
D00054
| - | - | 1件: 17 17 |
165 | 1,2-Dihexadecanoyl-sn-Glycero-3-Phospho-(1-raac-glycerol) | 1件: Glycerin Glycerin | 1件: D00028
D00028
| - | - | 1件: 79 79 |
166 | 1,5 (Butylimino)-1,5-dideoxy-D-glucitol | 1件: Sorbitol Sorbitol | 1件: D00096
D00096
| - | - | 1件: 299 299 |
167 | 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c | - | - | - | - | 1件: 46 46 |
168 | 1- Deoxygalactonojirimycin | - | - | - | - | 1件: 19 19 |
169 | 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride | 1件: Piperazine Piperazine | 6件: D00807
D00807
,
D01393
,
D02127
,
D02145
,
D05486
,
D06224
| - | - | 1件: 58 58 |
170 | 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 |
171 | 1-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-1H-INDOLE-2-BUTANOIC ACID | 2件: Butyric Acid Butyric Acid, Indole | 1件: D05866
D05866
| - | - | 1件: 51 51 |
172 | 1-20190 | - | - | - | - | 1件: 93 93 |
173 | 1-22460 | - | - | - | - | 1件: 51 51 |
174 | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid | - | - | - | - | 1件: 299 299 |
175 | 1-Deoxygalactonojirimycin | 1件: Migalastat Migalastat | 1件: D10359
D10359
| - | - | 1件: 19 19 |
176 | 1-deoxygalactonojirimycin hydrochloride | 1件: Migalastat Migalastat | 1件: D10359
D10359
| - | - | 1件: 19 19 |
177 | 1-deoxynojirimycin | 1件: Duvoglustat Duvoglustat | 1件: D09605
D09605
| 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 |
178 | 1-deoxynojirimycin hydrochloride | 1件: Duvoglustat Duvoglustat | 1件: D09605
D09605
| 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 |
179 | 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone | - | - | - | - | 1件: 13 13 |
180 | 1. Tesofensine (NS 2330) | 1件: Tesofensine Tesofensine | - | - | - | 1件: 6 6 |
181 | 1.0 mg Lu AE04621 | - | - | - | - | 1件: 6 6 |
182 | 1.0 mg rasagiline mesylate | 1件: Rasagiline Rasagiline | 3件: D02562
D02562
,
D08469
,
D10829
| 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
183 | 1.0 mg RPC103 | - | - | - | - | 1件: 97 97 |
184 | 1.0 mg RPC1063 | - | - | - | - | 1件: 97 97 |
185 | 1.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 |
186 | 1.0mg RPC1063 | - | - | - | - | 1件: 13 13 |
187 | 1.2 mg Lu AE04621 | - | - | - | - | 1件: 6 6 |
188 | 1.2 mg ZGN-440 for injectable suspension | - | - | - | - | 1件: 193 193 |
189 | 1.8 mg ZGN-440 for injectable suspension | - | - | - | - | 1件: 193 193 |
190 | 1.Remicade | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
191 | 10 mg | - | - | - | - | 1件: 96 96 |
192 | 10 mg Natura-alpha capsule | - | - | - | - | 1件: 97 97 |
193 | 10 mg/kg CNTO 136 | - | - | - | - | 1件: 49 49 |
194 | 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
195 | 10% intravenous immunoglobulin (IVIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 |
196 | 10% liquid formulation of human immunoglobulin | - | - | - | - | 1件: 14 14 |
197 | 10% Metronidazole Ointment | 1件: Metronidazole Metronidazole | 3件: D00409
D00409
,
D05016
,
D05017
| - | - | 1件: 96 96 |
198 | 10% nifedipine cream | 1件: Nifedipine Nifedipine | 1件: D00437
D00437
| 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 50 50 |
199 | 10% Nitroglycerine in Propylene Glycol, USP | 2件: Nitroglycerin Nitroglycerin, Propylene glycol | 2件: D00078
D00078
,
D00515
| - | - | 1件: 51 51 |
200 | 10-mg dose of E5501 2G tablet | - | - | - | - | 1件: 63 63 |
201 | 10-mg dose of E5501 cyclodextrin oral solution | - | - | - | - | 1件: 63 63 |
202 | 10-mg dose of E5501 lipid-based oral | - | - | - | - | 1件: 63 63 |
203 | 10-mg dose of E5501-P21% powder | - | - | - | - | 1件: 63 63 |
204 | 10-nitro-9(E)-octadec-9-enoic acid | - | - | - | - | 1件: 86 86 |
205 | 100 | - | - | - | - | 2件: 6 6, 97 |
206 | 100 mg | - | - | - | - | 1件: 97 97 |
207 | 100 mg AP1189 | - | - | - | - | 1件: 222 222 |
208 | 100 mg ELX (VX-445) / 50 mg TEZ / 75 mg IVA FDC | - | - | - | - | 1件: 299 299 |
209 | 100 mg ELX /50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 |
210 | 100 mg ELX/50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 |
211 | 100 mg ELX/50 mg TEZ/75 mg IVA fixed dose combination | - | - | - | - | 1件: 299 299 |
212 | 100 mg LX3305 QD | - | - | - | - | 1件: 46 46 |
213 | 100 mg TEZ/150 mg IVA FDC | - | - | - | - | 1件: 299 299 |
214 | 100 mg VX-445 /50 mg TEZ/75 mg IVA FDC | - | - | - | - | 1件: 299 299 |
215 | 100 mg VX-445/50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 |
216 | 100 mg/m2 dose | - | - | - | - | 1件: 299 299 |
217 | 100 µg Brimonidine Tartrate Implant | 1件: Brimonidine Brimonidine | 2件: D02076
D02076
,
D07540
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 90 90 |
218 | 100-mg ELX (VX-445) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 |
219 | 100-mg ELX (VX-455) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 |
220 | 100-mg ELX / 50-mg TEZ / 75 -mg | - | - | - | - | 1件: 299 299 |
221 | 100-mg ELX / 50-mg TEZ / 75 -mg IVA FDC | - | - | - | - | 1件: 299 299 |
222 | 100-mg VX-445 / 50-mg TEZ / 75- mg IVA FDC | - | - | - | - | 1件: 299 299 |
223 | 100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 |
224 | 100-mg VX-445 /50-mg TEZ/75-mg | - | - | - | - | 1件: 299 299 |
225 | 100-mg VX-445/50-mg TEZ/75-mg IVA FDC | - | - | - | - | 1件: 299 299 |
226 | 1000 IU D3 | - | - | - | - | 1件: 96 96 |
227 | 10000IU vitamin D | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 |
228 | 1000mg RTX Group | - | - | - | - | 1件: 46 46 |
229 | 100g ELX / 50mg TEZ / 75mg IVA | - | - | - | - | 1件: 299 299 |
230 | 100mcg rhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: D05364
D05364
| 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 |
231 | 100mg ELX/50mg TEZ /75mg IVA | - | - | - | - | 1件: 299 299 |
232 | 100mg VX-445/50mg TEZ /75mg IVA FDC | - | - | - | - | 1件: 299 299 |
233 | 111JC101 | - | - | - | - | 1件: 25 25 |
234 | 118-42-3 | - | - | - | - | 1件: 46 46 |
235 | 11C-ACETATE | 2件: Acetate Acetate, Acetic acid C-11 | - | - | - | 3件: 13 13, 86, 88 |
236 | 11C-BMS-986196 | - | - | - | - | 1件: 13 13 |
237 | 11C-CSar | - | - | - | - | 2件: 93 93, 94 |
238 | 11C-flumazenil | 1件: Flumazenil Flumazenil | 1件: D00697
D00697
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 206 206 |
239 | 11C-MCI | - | - | - | - | 1件: 13 13 |
240 | 11C-PBR28 | - | - | - | - | 2件: 6 6, 13 |
241 | 11C-PiB | - | - | - | - | 2件: 6 6, 13 |
242 | 11C-Raclopride | 1件: Raclopride Raclopride | - | - | - | 1件: 6 6 |
243 | 11C]-methionine | 1件: Methionine Methionine | 2件: D00019
D00019
,
D04983
| - | - | 1件: 34 34 |
244 | 11C]-PK-11195 | - | - | - | - | 1件: 13 13 |
245 | 11C]flumazenil | 1件: Flumazenil Flumazenil | 1件: D00697
D00697
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 13 13 |
246 | 11C]PBR28 | - | - | - | - | 1件: 6 6 |
247 | 11C]SMW139 | - | - | - | - | 1件: 6 6 |
248 | 12 lead electrocardiogram | - | - | - | - | 1件: 19 19 |
249 | 12 mg/kg GSK2402968 | - | - | - | - | 1件: 113 113 |
250 | 12-Lead ECG | - | - | - | - | 2件: 140 140, 144 |
251 | 120 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
252 | 124I-AT03 | - | - | - | - | 1件: 28 28 |
253 | 124I-labeled monoclonal antibody Mu 11-1F4 | - | - | - | - | 1件: 28 28 |
254 | 124I-p5+14 Injection | - | - | - | - | 1件: 28 28 |
255 | 125 | - | - | - | - | 1件: 6 6 |
256 | 129Xe Hyperpolarized | - | - | - | - | 1件: 86 86 |
257 | 129Xe Small and Large Human Lung Coil | - | - | - | - | 1件: 299 299 |
258 | 12S-IT | - | - | - | - | 1件: 19 19 |
259 | 13 valent conjugated pneumococcal vaccine | - | - | - | - | 1件: 265 265 |
260 | 13-15mg/kg/d Ursodeoxycholic | - | - | - | - | 1件: 93 93 |
261 | 13-PCV Booster | - | - | - | - | 1件: 13 13 |
262 | 13-valent pneumococcal conjugate vaccine | - | - | - | - | 2件: 46 46, 53 |
263 | 13-valent pneumococcal conjugate vaccine (13-PCV) | - | - | - | - | 1件: 13 13 |
264 | 13-valent pneumococcal conjugated vaccine (PCV13) | - | - | - | - | 1件: 96 96 |
265 | 1393641-34-3 | - | - | - | - | 1件: 13 13 |
266 | 13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT) | 1件: Spirulina platensis Spirulina platensis | - | - | - | 1件: 299 299 |
267 | 13NH3 PET/CT scan | - | - | - | - | 1件: 84 84 |
268 | 146368 | - | - | - | - | 1件: 271 271 |
269 | 14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration | - | - | - | - | 3件: 13 13, 96, 97 |
270 | 15 mg fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
271 | 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
272 | 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
273 | 15 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
274 | 15 O Water | 1件: Water Water | 1件: D00001
D00001
| - | - | 1件: 19 19 |
275 | 15 or 45 mg | - | - | - | - | 1件: 67 67 |
276 | 15-O labeled water | 1件: Water Water | 1件: D00001
D00001
| - | - | 1件: 46 46 |
277 | 150 mg | - | - | - | - | 1件: 97 97 |
278 | 150 mg double-blinded secukinumab | 1件: Secukinumab Secukinumab | 1件: D09967
D09967
| 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 |
279 | 150 mg GSK1265744B | - | - | - | - | 1件: 265 265 |
280 | 150 mg LX3305 QD | - | - | - | - | 1件: 46 46 |
281 | 150 mg open-label secukinumab | 1件: Secukinumab Secukinumab | 1件: D09967
D09967
| 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 |
282 | 150-mg IVACAFTOR | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
283 | 1500mg mesalazine pellets | 1件: Mesalazine Mesalazine | 1件: D00377
D00377
| - | - | 1件: 97 97 |
284 | 150mg CXA-10 | 1件: CXA-10 CXA-10 | - | - | - | 1件: 86 86 |
285 | 150mg IVACAFTOR | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
286 | 15N ammonium chloride (15NH4Cl) | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: D01139
D01139
| - | - | 1件: 251 251 |
287 | 15N2-tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 |
288 | 15O H2O | - | - | - | - | 1件: 6 6 |
289 | 15O]H2O | - | - | - | - | 1件: 6 6 |
290 | 16,5% Cutaquig | - | - | - | - | 1件: 65 65 |
291 | 1639325-43-1 | - | - | - | - | 1件: 254 254 |
292 | 1643368-58-4 | - | - | - | - | 2件: 53 53, 160 |
293 | 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione | - | - | - | - | 1件: 41 41 |
294 | 171 | - | - | - | - | 1件: 86 86 |
295 | 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 |
296 | 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 |
297 | 18 FDG | - | - | - | - | 1件: 145 145 |
298 | 18-22mg/kg/d Ursodeoxycholic | - | - | - | - | 1件: 93 93 |
299 | 18-F]DPA-714 | - | - | - | - | 1件: 127 127 |
300 | 18-FDTBZ | - | - | - | - | 1件: 6 6 |
301 | 18F florbetaben | 1件: Florbetaben (18F) Florbetaben (18F) | - | - | - | 1件: 6 6 |
302 | 18F- DTBZ | - | - | - | - | 1件: 6 6 |
303 | 18F-AV-133 | 1件: Florbenazine F-18 Florbenazine F-18 | - | - | - | 1件: 6 6 |
304 | 18F-AV-1451 | - | - | - | - | 3件: 5 5, 7, 127 |
305 | 18F-AV-45 | - | - | - | - | 2件: 6 6, 127 |
306 | 18F-deoxyglucose (FDG) | - | - | - | - | 1件: 57 57 |
307 | 18F-DOPA | - | - | - | - | 2件: 6 6, 75 |
308 | 18F-DOPA PET | - | - | - | - | 1件: 6 6 |
309 | 18F-DPA-714 and 18F-FDG | 1件: Fludeoxyglucose (18F) Fludeoxyglucose (18F) | - | - | - | 1件: 13 13 |
310 | 18F-DTBZ | - | - | - | - | 1件: 6 6 |
311 | 18F-DTBZ AV-133 | - | - | - | - | 1件: 6 6 |
312 | 18F-FDG | 1件: Fludeoxyglucose (18F) Fludeoxyglucose (18F) | - | - | - | 13件: 5 5, 6, 7, 8, 13, 41, 46, 53, 84, 85, 96, 127, 300 |
313 | 18F-fluorodeoxyglucose | - | - | - | - | 1件: 84 84 |
314 | 18F-FSPG | 1件: Florilglutamic acid F-18 Florilglutamic acid F-18 | - | - | - | 1件: 84 84 |
315 | 18F-FTC-146 | - | - | - | - | 1件: 206 206 |
316 | 18F-GE-180 | 1件: Flutriciclamide F-18 Flutriciclamide F-18 | - | - | - | 1件: 46 46 |
317 | 18F-PM-PBB3 | - | - | - | - | 1件: 13 13 |
318 | 18F-RO6958948 | - | - | - | - | 3件: 5 5, 7, 127 |
319 | 18F] LBT-999 | - | - | - | - | 1件: 6 6 |
320 | 18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane | - | - | - | - | 1件: 6 6 |
321 | 18F]DPA-714 | - | - | - | - | 2件: 13 13, 127 |
322 | 18F]FE-PE2I | - | - | - | - | 1件: 6 6 |
323 | 18F]Fluoride | - | - | - | - | 1件: 271 271 |
324 | 18F]MC225 | - | - | - | - | 1件: 6 6 |
325 | 18F]PEG-Folate | 1件: Folic acid Folic acid | 1件: D00070
D00070
| - | - | 2件: 41 41, 46 |
326 | 18FDG PET/CT scan | - | - | - | - | 1件: 84 84 |
327 | 19 nor vitamin d | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 |
328 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 |
329 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 |
330 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 |
331 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 |
332 | 1H-Pyrazol | 1件: Pyrazole Pyrazole | - | - | - | 5件: 2 2, 28, 46, 75, 154 |
333 | 1mg budesonide effervescent tablet for orodispersible use | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
334 | 1mg RPC1063 | - | - | - | - | 1件: 96 96 |
335 | 1mg/kg/hr TXA intravenous infusion till the last suture | - | - | - | - | 1件: 70 70 |
336 | 1mL prefilled syringes | - | - | - | - | 1件: 107 107 |
337 | 2 - Excipients | - | - | - | - | 1件: 13 13 |
338 | 2 mA Transcranial Direct Current Stimulation | - | - | - | - | 1件: 13 13 |
339 | 2 mg perampanel | 1件: Perampanel Perampanel | 1件: D08964
D08964
| 4件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4 💬 | 16件: Amphetamine addiction Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 6 6 |
340 | 2 million hMSC/kg | - | - | - | - | 1件: 46 46 |
341 | 2 ml of whole blood sample will be collected on EDTA tube | 1件: Edetic acid Edetic acid | 8件: D00052
D00052
,
D00571
,
D01802
,
D03943
,
D03944
,
D03945
,
D03946
,
D03947
| - | - | 1件: 51 51 |
342 | 2 x 10 mg Natura-alpha capsules | - | - | - | - | 1件: 97 97 |
343 | 2% Chlorhexidine solution wipes | 1件: Chlorhexidine Chlorhexidine | 4件: D00858
D00858
,
D01345
,
D03463
,
D07668
| - | - | 1件: 299 299 |
344 | 2% lignocaine | 1件: Lidocaine Lidocaine | 3件: D00358
D00358
,
D02086
,
D08127
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 84 84 |
345 | 2% sodium chondroitin sulfate | 2件: Chondroitin sulfate Chondroitin sulfate, Sulfate ion | - | - | - | 1件: 226 226 |
346 | 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid | - | - | - | - | 1件: 28 28 |
347 | 2'-Fucosyllactose | - | - | - | - | 2件: 96 96, 97 |
348 | 2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING | 1件: Ribose Ribose | - | - | - | 1件: 131 131 |
349 | 2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING GLIAL FIBRILLARY ACIDIC PROTEIN MESSENGER RIBONUCLEIC ACID | 1件: Ribose Ribose | - | - | - | 1件: 131 131 |
350 | 2(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID | - | - | - | - | 2件: 19 19, 65 |
351 | 2,3-dihydroxybutanedioic acid | - | - | - | - | 1件: 299 299 |
352 | 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide | - | - | - | - | 1件: 6 6 |
353 | 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid | 1件: Benzoic acid Benzoic acid | 1件: D00038
D00038
| - | - | 1件: 51 51 |
354 | 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester | - | - | - | - | 1件: 13 13 |
355 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat | - | - | - | - | 1件: 28 28 |
356 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate | - | - | - | - | 1件: 28 28 |
357 | 2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide | - | - | - | - | 1件: 86 86 |
358 | 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE | - | - | - | - | 2件: 6 6, 162 |
359 | 2-amino-4-(methyl[11C]sulfanyl)butanoic acid | 2件: Butyric Acid Butyric Acid, Methionine | 3件: D00019
D00019
,
D04983
,
D05866
| - | - | 1件: 34 34 |
360 | 2-aminoethanethiol | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 2件: 19 19, 299 |
361 | 2-CdA | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
362 | 2-CdA, 2-chloro-2'-deoxy-beta-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
363 | 2-CdA, 2-chloro-2'-deoxy-ß-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
364 | 2-CdA, 2-chloro-2?-deoxy-beta-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
365 | 2-CdA, 2-chloro-2?-deoxy-ß-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
366 | 2-CdA, 2-chloro-2’-deoxy-beta-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
367 | 2-CdA, 2-chloro-2’-deoxy-ß-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
368 | 2-chloro-2'-deoxy-beta-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
369 | 2-chloro-2'-deoxy-ß-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
370 | 2-chloro-2'-deoxyadenosine (2-CdA) | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
371 | 2-chloro-2'-deoxyadenosine, 2CdA | - | - | - | - | 1件: 13 13 |
372 | 2-chloro-2?-deoxy-beta-D-adenosine | 1件: Adenosine Adenosine | 1件: D00045
D00045
| 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
373 | 2-chloro-2?-deoxy-ß-D-adenosine | 1件: Adenosine Adenosine | 1件: D00045
D00045
| 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
374 | 2-chloro-2’-deoxy-beta-D-adenosine | 1件: Adenosine Adenosine | 1件: D00045
D00045
| 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
375 | 2-chloro-2’-deoxy-beta-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
376 | 2-chloro-2’-deoxy-ß-D-adenosine | 1件: Adenosine Adenosine | 1件: D00045
D00045
| 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
377 | 2-chloro-2’-deoxy-ß-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
378 | 2-chloro-2’-deoxyadenosine (2-CdA) | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
379 | 2-deoxy-2 [F-18] fluoro-2-d-glucose | 2件: D-glucose D-glucose, Dextrose, unspecified form | 1件: D00009
D00009
| - | - | 1件: 49 49 |
380 | 2-HOBA | 1件: 2-(aminomethyl)phenol 2-(aminomethyl)phenol | - | - | - | 1件: 46 46 |
381 | 2-hour Holter Monitor | 1件: Methamidophos Methamidophos | - | - | - | 1件: 19 19 |
382 | 2-Hydroxybenzoic acid | 1件: Salicylic acid Salicylic acid | 1件: D00097
D00097
| - | - | 1件: 97 97 |
383 | 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN | 2件: Betadex Betadex, Hydroxypropyl betadex | 1件: D02401
D02401
| - | - | 1件: 19 19 |
384 | 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide | 1件: Acetamide Acetamide | - | - | - | 1件: 86 86 |
385 | 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt | 1件: Hydroxide ion Hydroxide ion | - | - | - | 1件: 46 46 |
386 | 2.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 |
387 | 20 mg | - | - | - | - | 1件: 97 97 |
388 | 20 mg BID of PF-02545920 | - | - | - | - | 1件: 8 8 |
389 | 20 mg fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
390 | 20 mg GA | - | - | - | - | 1件: 13 13 |
391 | 20 mg MitoQ | - | - | - | - | 1件: 13 13 |
392 | 20 mg sildenafil citrate by mouth | 1件: Sildenafil Sildenafil | 2件: D02229
D02229
,
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
393 | 20 mg/ml Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
394 | 200 mg BIA 6-512 | 1件: BIA BIA | - | - | - | 1件: 6 6 |
395 | 200 mg LX3305 QD | - | - | - | - | 1件: 46 46 |
396 | 200 mg/m2 dose | - | - | - | - | 1件: 299 299 |
397 | 200 µg Brimonidine Tartrate Implant | 1件: Brimonidine Brimonidine | 2件: D02076
D02076
,
D07540
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 90 90 |
398 | 200106 or EMD 28162 | - | - | - | - | 1件: 13 13 |
399 | 200mg Cannabidiol by capsules twice daily | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 46 46 |
400 | 2011-2012 seasonal flu vaccine Intramuscular | - | - | - | - | 2件: 3 3, 113 |
401 | 2011-2012 seasonal flu vaccine Subcutaneous | - | - | - | - | 2件: 3 3, 113 |
402 | 201600930 | - | - | - | - | 1件: 2 2 |
403 | 207-3120 | - | - | - | - | 1件: 6 6 |
404 | 20mg daily citalopram | 1件: Citalopram Citalopram | 2件: D00822
D00822
,
D07704
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 8 8 |
405 | 20mg/0.5ml GA | - | - | - | - | 1件: 13 13 |
406 | 20mg/0.5ml glatiramer acetate | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
407 | 225mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 |
408 | 23-PPV | - | - | - | - | 1件: 13 13 |
409 | 23-valent pneumococcal polysaccharide vaccine | - | - | - | - | 3件: 13 13, 46, 53 |
410 | 23-valent pneumococcal polysaccharide vaccine (23-PPV) | - | - | - | - | 1件: 13 13 |
411 | 23-valent polysaccharide pneumococcal vaccine | - | - | - | - | 1件: 96 96 |
412 | 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM) | - | - | - | - | 2件: 96 96, 97 |
413 | 2387066 | - | - | - | - | 1件: 56 56 |
414 | 240mg Amantadine HCl ER tablets | 1件: Amantadine Amantadine | 2件: D00777
D00777
,
D07441
| 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 |
415 | 25 mg BIA9 1067 | - | - | - | - | 1件: 6 6 |
416 | 25 mg Ongentys | 1件: Opicapone Opicapone | 1件: D10825
D10825
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
417 | 25 mg Ontamalimab | 1件: Ontamalimab Ontamalimab | - | - | - | 2件: 96 96, 97 |
418 | 25% MTD sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
419 | 25-Hydroxyvitamin D3 | 1件: Calcifediol Calcifediol | 1件: D00122
D00122
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 |
420 | 250 mg CK-2017357 | - | - | - | - | 2件: 2 2, 11 |
421 | 250 mg LX3305 BID | - | - | - | - | 1件: 46 46 |
422 | 250 mg LX3305 QD | - | - | - | - | 1件: 46 46 |
423 | 250mg mesalazine pellets | 1件: Mesalazine Mesalazine | 1件: D00377
D00377
| - | - | 1件: 97 97 |
424 | 25330 | - | - | - | - | 1件: 6 6 |
425 | 2593 | - | - | - | - | 1件: 46 46 |
426 | 25mcg rhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: D05364
D05364
| 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 |
427 | 25OH-Vitamin D | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 13 13 |
428 | 2622U90 Duramycin | 1件: Lancovutide Lancovutide | - | - | - | 1件: 299 299 |
429 | 26866138 | - | - | - | - | 1件: 28 28 |
430 | 29180.00.00, 34681.00.00, 34681.01.00, 34681.02.00 | - | - | - | - | 1件: 113 113 |
431 | 291844 | - | - | - | - | 2件: 246 246, 299 |
432 | 2B3-201 | - | - | - | - | 1件: 13 13 |
433 | 2L polyethylene glycol/ascorbic acid | 2件: Ascorbic acid Ascorbic acid, Polyethylene glycol | 2件: D00018
D00018
,
D03370
| - | - | 1件: 97 97 |
434 | 2mg budesonide effervescent tablet for orodispersible use | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
435 | 2mg KPG-818 dose | - | - | - | - | 1件: 49 49 |
436 | 2S,4R-(-)-ketoconazole | 1件: Ketoconazole Ketoconazole | 1件: D00351
D00351
| 1件: CYP17A1 CYP17A1 💬 | 6件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬 | 1件: 75 75 |
437 | 2S,4R-(-)-ketoconazole, levoketoconazole | 2件: Ketoconazole Ketoconazole, Levoketoconazole | 2件: D00351
D00351
,
D10950
| 1件: CYP17A1 CYP17A1 💬 | 6件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬 | 1件: 75 75 |
438 | 3 mg [14C]-A4250 capsule | - | - | - | - | 3件: 93 93, 297, 338 |
439 | 3 mg Melatonin | 1件: Melatonin Melatonin | 1件: D08170
D08170
| 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
440 | 3 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
441 | 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
442 | 3 mg tropicamide | 1件: Tropicamide Tropicamide | 1件: D00397
D00397
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 |
443 | 3 mg/kg GSK2402968 | - | - | - | - | 1件: 113 113 |
444 | 3 MPDN pulse + PDN | - | - | - | - | 1件: 50 50 |
445 | 3 MPDN pulse + PDN + CSA | - | - | - | - | 1件: 50 50 |
446 | 3 MPDN pulse + PDN + MTX | - | - | - | - | 1件: 50 50 |
447 | 3,4-DIAMINOPYRIDINE | - | - | - | - | 2件: 12 12, 13 |
448 | 3,4-Diaminopyridine Phosphate | 1件: Phosphate ion Phosphate ion | - | - | - | 1件: 3 3 |
449 | 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate | - | - | - | - | 1件: 6 6 |
450 | 3-(3,4-Dihydroxyphenyl)-L-alanine | 2件: Alanine Alanine, Levodopa | 2件: D00012
D00012
,
D00059
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
451 | 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID | 1件: Pyrazole Pyrazole | - | - | - | 1件: 28 28 |
452 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- | - | - | - | - | 1件: 93 93 |
453 | 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt | - | - | - | - | 2件: 51 51, 85 |
454 | 3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1), Ferric (3-hydroxy-2-methyl-4-pyrone), Tris-maltol-iron (III), Tri=maltol-iron (III) | 1件: Tromethamine Tromethamine | 1件: D00396
D00396
| - | - | 2件: 96 96, 97 |
455 | 3-methyl-1-phenyl-4, 5-dihydro-1H-pyrazol-5-one. | 1件: Pyrazole Pyrazole | - | - | - | 1件: 2 2 |
456 | 3.2 mg intranasal carbetocin | 1件: Carbetocin Carbetocin | 1件: D07229
D07229
| 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 193 193 |
457 | 30 or 60 mg | - | - | - | - | 1件: 67 67 |
458 | 30 or 90 mg | - | - | - | - | 1件: 67 67 |
459 | 30-hour ambulatory sampling of intestinal fluid | - | - | - | - | 1件: 83 83 |
460 | 300 mg double-blinded secukinumab | 1件: Secukinumab Secukinumab | 1件: D09967
D09967
| 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 |
461 | 300 mg LX3305 QD | - | - | - | - | 1件: 46 46 |
462 | 300mg Gemcabene | 1件: Gemcabene Gemcabene | - | - | - | 1件: 265 265 |
463 | 3108006977 | - | - | - | - | 1件: 94 94 |
464 | 320mg Amantadine HCl ER tablets | 1件: Amantadine Amantadine | 2件: D00777
D00777
,
D07441
| 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 |
465 | 331731-18-1 | - | - | - | - | 4件: 46 46, 96, 97, 271 |
466 | 3400930060797 | - | - | - | - | 1件: 36 36 |
467 | 3400935113276 | - | - | - | - | 1件: 56 56 |
468 | 35565011 | - | - | - | - | 1件: 46 46 |
469 | 35mg | - | - | - | - | 2件: 50 50, 107 |
470 | 36-482-Hyaluronoglucosaminidase PH20 (rHuPH20) | 1件: Hyaluronidase Hyaluronidase | 3件: D04455
D04455
,
D04456
,
D06604
| - | - | 1件: 65 65 |
471 | 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-oic acid | - | - | - | - | 1件: 93 93 |
472 | 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-oic acid | - | - | - | - | 1件: 93 93 |
473 | 3D electrocardiographic mapping (ECM) | - | - | - | - | 1件: 58 58 |
474 | 3H-cholesterol bound to albumin | 1件: Cholesterol Cholesterol | 1件: D00040
D00040
| - | - | 2件: 259 259, 261 |
475 | 3He Human Lung Coil | - | - | - | - | 1件: 299 299 |
476 | 3K3A-APC Protein | - | - | - | - | 1件: 2 2 |
477 | 3TC | - | - | - | - | 2件: 265 265, 325 |
478 | 4 cholesten-3-one, oxime | - | - | - | - | 1件: 2 2 |
479 | 4 mA Transcranial Direct Current Stimulation | - | - | - | - | 1件: 13 13 |
480 | 4 mg perampanel | 1件: Perampanel Perampanel | 1件: D08964
D08964
| 4件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4 💬 | 16件: Amphetamine addiction Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 6 6 |
481 | 4 mg/kg CNTO 136 | - | - | - | - | 1件: 49 49 |
482 | 4 million hMSC/kg | - | - | - | - | 1件: 46 46 |
483 | 4% chlorhexidine gluconate liquid skin cleanser | 1件: Chlorhexidine Chlorhexidine | 4件: D00858
D00858
,
D01345
,
D03463
,
D07668
| - | - | 1件: 299 299 |
484 | 4'-iodo-4'-deoxydoxorubicin | 1件: Iodine Iodine | 1件: D00108
D00108
| - | - | 1件: 28 28 |
485 | 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base | 1件: Methane Methane | - | - | - | 1件: 2 2 |
486 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide | 1件: Pyrazole Pyrazole | - | - | - | 1件: 46 46 |
487 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide | 1件: Pyrazole Pyrazole | - | - | - | 1件: 46 46 |
488 | 4-Aminopyridine | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 3 3, 13 |
489 | 4-Aminosalicylic acid | 1件: Aminosalicylic acid Aminosalicylic acid | 1件: D00162
D00162
| - | - | 1件: 96 96 |
490 | 4-Aminosalicylic acid extended release granules | 1件: Aminosalicylic acid Aminosalicylic acid | 1件: D00162
D00162
| - | - | 1件: 96 96 |
491 | 4-AP | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
492 | 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 5 5 |
493 | 4-Benzyl-2-naphthalen-1-yl-1,2,4- thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 |
494 | 4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 |
495 | 4-cholesten-3-one, oxime | - | - | - | - | 2件: 2 2, 3 |
496 | 4-cholesten-3-one,oxime | - | - | - | - | 1件: 3 3 |
497 | 4-Methylpyrazole | 1件: Fomepizole Fomepizole | 1件: D00707
D00707
| 3件: ADH1A ADH1A, ADH1B, ADH1C 💬 | 9件: Alcoholic liver disease Alcoholic liver disease, Drug metabolism - cytochrome P450, Fatty acid degradation, Glycolysis / Gluconeogenesis, Metabolic pathways, Metabolism of xenobiotics by cytochrome P450, Pyruvate metabolism, Retinol metabolism, Tyrosine metabolism 💬 | 1件: 301 301 |
498 | 4-PBA | - | - | - | - | 1件: 231 231 |
499 | 4-phenylbutyrate | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 2件: 251 251, 299 |
500 | 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | 1件: 46 46 |
501 | 4.2% NaCl/Inhalation solution | - | - | - | - | 1件: 299 299 |
502 | 4.5 mg Naltrexone | 1件: Naltrexone Naltrexone | 2件: D02095
D02095
,
D05113
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
503 | 40 mg | - | - | - | - | 1件: 96 96 |
504 | 40 mg GA | - | - | - | - | 2件: 2 2, 13 |
505 | 40 mg glatiramer acetate | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 2件: 2 2, 13 |
506 | 40 mg Glatiramer acetato | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
507 | 40 mg MSB11022 | - | - | - | - | 5件: 46 46, 96, 97, 107, 271 |
508 | 40 MG- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL | - | - | - | - | 1件: 107 107 |
509 | 400 mg BIA 5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 |
510 | 400 mg LX3305 QD | - | - | - | - | 1件: 46 46 |
511 | 400 µg Brimonidine Tartrate Implant | 1件: Brimonidine Brimonidine | 2件: D02076
D02076
,
D07540
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 90 90 |
512 | 400mg Cannabidiol by capsules twice daily | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 46 46 |
513 | 40mg of MitoQ | - | - | - | - | 1件: 13 13 |
514 | 42942019 | - | - | - | - | 4件: 46 46, 96, 97, 271 |
515 | 44/154/85-C | - | - | - | - | 1件: 50 50 |
516 | 44/196/81-C | - | - | - | - | 1件: 50 50 |
517 | 45 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
518 | 450 mg | - | - | - | - | 1件: 97 97 |
519 | 4AU76 | - | - | - | - | 1件: 86 86 |
520 | 4cc of lidocaïne® | - | - | - | - | 1件: 149 149 |
521 | 4D-125 IVT Injection | - | - | - | - | 1件: 90 90 |
522 | 4D-310 | - | - | - | - | 1件: 19 19 |
523 | 4D-710 | - | - | - | - | 1件: 299 299 |
524 | 5 ASA, enemas, suppositories, corticosteroids | - | - | - | - | 1件: 97 97 |
525 | 5 mg Melatonin | 1件: Melatonin Melatonin | 1件: D08170
D08170
| 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
526 | 5 mg Montelukast | 1件: Montelukast Montelukast | 2件: D00529
D00529
,
D08229
| 1件: CYSLTR1 CYSLTR1 💬 | 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
527 | 5 mg Prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 44 44 |
528 | 5% glucose water solution | 2件: Dextrose, unspecified form Dextrose, unspecified form, Water | 1件: D00001
D00001
| - | - | 1件: 2 2 |
529 | 5% lidocaine/5 mg/ml 0.02% estradiol compound cream | 2件: Estradiol Estradiol, Lidocaine | 11件: D00105
D00105
,
D00358
,
D01413
,
D01617
,
D01953
,
D02086
,
D04061
,
D04063
,
D04064
,
D04065
,
D08127
| 7件: ESR1 ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 13件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Breast cancer, Chemical carcinogenesis - receptor activation, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway 💬 | 1件: 226 226 |
530 | 5% sildenafil cream | 1件: Sildenafil Sildenafil | 2件: D02229
D02229
,
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 50 50 |
531 | 5,6,7,8-tetrahydrobiopterin | 1件: Sapropterin Sapropterin | 1件: D08505
D08505
| - | - | 1件: 240 240 |
532 | 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole | - | - | - | - | 1件: 113 113 |
533 | 5-[4-[2-(5-(1-hydroxyethyl)-2- pyridinyl)ethoxy]benzyl]-2,4- thiazolidinedione hydrochloride | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 |
534 | 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 |
535 | 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]METHYL]-2,4-THIAZOLIDINEDIONE HYDROCHLORIDE | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 |
536 | 5-amino salicylic acid | 1件: Salicylic acid Salicylic acid | 1件: D00097
D00097
| - | - | 1件: 97 97 |
537 | 5-amino salicylic acid (5-ASA) | 2件: Mesalazine Mesalazine, Salicylic acid | 2件: D00097
D00097
,
D00377
| - | - | 1件: 97 97 |
538 | 5-amino-2-hydroxybenzoic acid | 1件: Salicylic acid Salicylic acid | 1件: D00097
D00097
| - | - | 1件: 97 97 |
539 | 5-aminolevulinic acid | 1件: Aminolevulinic acid Aminolevulinic acid | 2件: D02908
D02908
,
D07567
| - | - | 1件: 96 96 |
540 | 5-Aminosalicyclic acid | - | - | - | - | 1件: 97 97 |
541 | 5-Aminosalicyl acid | - | - | - | - | 1件: 96 96 |
542 | 5-aminosalicylate (Pentasa, Ferring) | - | - | - | - | 2件: 96 96, 97 |
543 | 5-Aminosalicylic acid | 2件: Aminosalicylic acid Aminosalicylic acid, Mesalazine | 2件: D00162
D00162
,
D00377
| - | - | 2件: 96 96, 97 |
544 | 5-Aminosalicylic acid (5-ASA) | 2件: Aminosalicylic acid Aminosalicylic acid, Mesalazine | 2件: D00162
D00162
,
D00377
| - | - | 1件: 97 97 |
545 | 5-Aminosalicylic acid(5-ASA) and/or Prednisone | 3件: Aminosalicylic acid Aminosalicylic acid, Mesalazine, Prednisone | 3件: D00162
D00162
,
D00377
,
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
546 | 5-ASA | 1件: Mesalazine Mesalazine | 1件: D00377
D00377
| - | - | 2件: 96 96, 97 |
547 | 5-ASA (5-Aminosalicylate) | 1件: Mesalazine Mesalazine | 1件: D00377
D00377
| - | - | 1件: 97 97 |
548 | 5-ASA MMx | 1件: Mesalazine Mesalazine | 1件: D00377
D00377
| - | - | 1件: 97 97 |
549 | 5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin | 1件: Chlorine Chlorine | - | - | - | 2件: 46 46, 271 |
550 | 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | - | - | - | - | 1件: 8 8 |
551 | 5-HTP | - | - | - | - | 2件: 96 96, 97 |
552 | 5-Hydroxytryptophan / Vitamin B6 | 1件: Pyridoxine Pyridoxine | 2件: D02179
D02179
,
D08454
| - | - | 1件: 206 206 |
553 | 5-Methyl-1-Phenyl-2-1-(H)-Pyridone | - | - | - | - | 1件: 228 228 |
554 | 5-methyltetrahydrofolate and vitamin B12 | 1件: Cyanocobalamin Cyanocobalamin | 4件: D00166
D00166
,
D03615
,
D03616
,
D03617
| - | - | 1件: 299 299 |
555 | 5-MTHF | - | - | - | - | 1件: 337 337 |
556 | 5-probe cocktail | - | - | - | - | 1件: 254 254 |
557 | 50 mg | - | - | - | - | 1件: 97 97 |
558 | 50 mg AP1189 | - | - | - | - | 1件: 46 46 |
559 | 50 mg BIA 9 1067 | 1件: BIA BIA | - | - | - | 1件: 6 6 |
560 | 50 mg ELX/25 mg TEZ/37.5 mg IVA | - | - | - | - | 1件: 299 299 |
561 | 50 mg ELX/25 mg TEZ/37.5 mg IVA fixed dose combination | - | - | - | - | 1件: 299 299 |
562 | 50 mg Etanercept | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
563 | 50 mg LX3305 QD | - | - | - | - | 1件: 46 46 |
564 | 50 mg Ongentys | 1件: Opicapone Opicapone | 1件: D10825
D10825
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
565 | 500 0500 0 | - | - | - | - | 1件: 19 19 |
566 | 500 mg CK-2017357 | - | - | - | - | 2件: 2 2, 11 |
567 | 500 mg LX3305 QD | - | - | - | - | 1件: 46 46 |
568 | 5000 IU D3 | - | - | - | - | 1件: 96 96 |
569 | 5000 IU of cholecalciferol | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 |
570 | 5000IU vitamin D | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 |
571 | 5009111000001105 | - | - | - | - | 1件: 43 43 |
572 | 500mg mesalazine pellets | 1件: Mesalazine Mesalazine | 1件: D00377
D00377
| - | - | 1件: 97 97 |
573 | 500mg RTX Group | - | - | - | - | 1件: 46 46 |
574 | 5057732 | - | - | - | - | 1件: 271 271 |
575 | 50mcg rhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: D05364
D05364
| 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 |
576 | 52069.00.01 | - | - | - | - | 1件: 13 13 |
577 | 534-1508 | - | - | - | - | 1件: 85 85 |
578 | 549-0261/F02-01 | - | - | - | - | 2件: 96 96, 97 |
579 | 552-02 | - | - | - | - | 2件: 53 53, 299 |
580 | 56/104/75-C | - | - | - | - | 1件: 50 50 |
581 | 5mg | - | - | - | - | 2件: 50 50, 107 |
582 | 6 alpha-ethylchenodeoxycholic acid (6-EDCA), OCA, INT-747 | - | - | - | - | 1件: 93 93 |
583 | 6 Mercaptopurine | 1件: Mercaptopurine Mercaptopurine | 2件: D00161
D00161
,
D04931
| 1件: HPRT1 HPRT1 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 2件: 96 96, 97 |
584 | 6 mg/kg GSK2402968 | - | - | - | - | 1件: 113 113 |
585 | 6 million hMSC/kg | - | - | - | - | 1件: 46 46 |
586 | 6% Hypertonic Saline (HS), 4mL | - | - | - | - | 1件: 299 299 |
587 | 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine | - | - | - | - | 1件: 38 38 |
588 | 6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate | - | - | - | - | 1件: 46 46 |
589 | 6-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine | - | - | - | - | 1件: 96 96 |
590 | 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid | - | - | - | - | 1件: 97 97 |
591 | 6-ECDCA | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
592 | 6-ethylchenodeoxycholic acid | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
593 | 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one | - | - | - | - | 1件: 2 2 |
594 | 6-Mercaptopurine | 1件: Mercaptopurine Mercaptopurine | 2件: D00161
D00161
,
D04931
| 1件: HPRT1 HPRT1 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 3件: 96 96, 97, 164 |
595 | 6-Mercaptopurine (Puri-Nethol) | 1件: Mercaptopurine Mercaptopurine | 2件: D00161
D00161
,
D04931
| 1件: HPRT1 HPRT1 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 1件: 96 96 |
596 | 6-MP | 1件: Mercaptopurine Mercaptopurine | 2件: D00161
D00161
,
D04931
| 1件: HPRT1 HPRT1 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 2件: 96 96, 97 |
597 | 600mg Gemcabene | 1件: Gemcabene Gemcabene | - | - | - | 1件: 265 265 |
598 | 6036937.00.01 | - | - | - | - | 1件: 6 6 |
599 | 64Cu]Cl2 | - | - | - | - | 1件: 171 171 |
600 | 64CuCl2 | - | - | - | - | 1件: 171 171 |
601 | 66215-101 | - | - | - | - | 1件: 86 86 |
602 | 683699 | - | - | - | - | 1件: 96 96 |
603 | 68Ga-BMV101 | - | - | - | - | 1件: 85 85 |
604 | 68Ga-BNOTA-PRGD2 | - | - | - | - | 1件: 46 46 |
605 | 68Ga-DOTA-TATE PET/MR and PET/CT imaging | 1件: Dotatate Dotatate | - | - | - | 1件: 238 238 |
606 | 68Ga-DOTANOC | - | - | - | - | 1件: 84 84 |
607 | 68Ga-DOTATATE | 2件: Dotatate Dotatate, Dotatate gallium Ga-68 | - | - | - | 3件: 75 75, 84, 238 |
608 | 68Ga-DOTATATE PET/CT | 2件: Dotatate Dotatate, Dotatate gallium Ga-68 | - | - | - | 1件: 84 84 |
609 | 68Ga-FAPI | - | - | - | - | 2件: 46 46, 300 |
610 | 68Ga-NEB | - | - | - | - | 3件: 46 46, 89, 280 |
611 | 6?-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
612 | 6a-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
613 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
614 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
615 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
616 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
617 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
618 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
619 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
620 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
621 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
622 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
623 | 6abeta - apomorphine-10,11-diol hydrochloride hemihydrate | 1件: Apomorphine Apomorphine | 2件: D02004
D02004
,
D07460
| 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
624 | 6aß - apomorphine-10,11-diol hydrochloride hemihydrate | 1件: Apomorphine Apomorphine | 2件: D02004
D02004
,
D07460
| 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
625 | 6R-BH4 | 1件: Sapropterin Sapropterin | 1件: D08505
D08505
| - | - | 3件: 86 86, 124, 240 |
626 | 7 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
627 | 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: D11431
D11431
| 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 |
628 | 7% Hypertonic Saline (HS) | - | - | - | - | 1件: 299 299 |
629 | 7% NaCl | - | - | - | - | 1件: 299 299 |
630 | 7% saline | - | - | - | - | 1件: 299 299 |
631 | 7-beta-Hydroxyepiandrosterone | 1件: 7-beta-Hydroxyepiandrosterone 7-beta-Hydroxyepiandrosterone | - | - | - | 1件: 6 6 |
632 | 7-valent Pneumococcal Conjugate vaccine | - | - | - | - | 1件: 46 46 |
633 | 70930.00.00 | - | - | - | - | 1件: 46 46 |
634 | 75 | - | - | - | - | 1件: 6 6 |
635 | 75 mg Ontamalimab | 1件: Ontamalimab Ontamalimab | - | - | - | 2件: 96 96, 97 |
636 | 75-mg IVACAFTOR | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
637 | 750 mg metformin and 7.5 g L-citrulline daily p.o. | 2件: Citrulline Citrulline, Metformin | 3件: D00944
D00944
,
D04966
,
D07706
| 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 113 113 |
638 | 750mg mesalazine pellets | 1件: Mesalazine Mesalazine | 1件: D00377
D00377
| - | - | 1件: 97 97 |
639 | 755nm Alexandrite Laser | - | - | - | - | 1件: 34 34 |
640 | 75mg CXA-10 | 1件: CXA-10 CXA-10 | - | - | - | 1件: 86 86 |
641 | 75mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 |
642 | 8-OHdG | 1件: 8-hydroxy-2'-deoxyguanosine 8-hydroxy-2'-deoxyguanosine | - | - | - | 1件: 6 6 |
643 | 80 mg DR-6MP | - | - | - | - | 1件: 96 96 |
644 | 800 mg ibuprofen/26.6 mg famotidine | 2件: Famotidine Famotidine, Ibuprofen | 5件: D00126
D00126
,
D00318
,
D01122
,
D04490
,
D06606
| 3件: HRH2 HRH2, PTGS1, PTGS2 💬 | 26件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - DNA adducts, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 107 107 |
645 | 80mg ELX / 40mg TEZ / 60mg IVA | - | - | - | - | 1件: 299 299 |
646 | 81mg aspirin | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: D00109
D00109
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 49 49 |
647 | 8594739041288 | - | - | - | - | 1件: 46 46 |
648 | 8699505952864 | - | - | - | - | 1件: 56 56 |
649 | 89 Zirconium Recombinant Human Alpha-N-Acetylglucosaminidase (rhNAGLU) (radiolabeled) | - | - | - | - | 1件: 19 19 |
650 | 89ZR-BEVACIZUMAB | 2件: Bevacizumab Bevacizumab, Bevacizumab zirconium Zr-89 | 1件: D06409
D06409
| 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 1件: 34 34 |
651 | 89Zr-DFO-CZP | - | - | - | - | 1件: 46 46 |
652 | 89Zr-SBC-103 | - | - | - | - | 1件: 19 19 |
653 | 9 mg/kg GSK2402968 | - | - | - | - | 1件: 113 113 |
654 | 9% Sodium Chloride (NaCl) IV | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 1件: 78 78 |
655 | 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxaline | - | - | - | - | 1件: 46 46 |
656 | 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER | 1件: Linoleic acid Linoleic acid | - | - | - | 2件: 2 2, 5 |
657 | 9.6 mg intranasal carbetocin | 1件: Carbetocin Carbetocin | 1件: D07229
D07229
| 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 193 193 |
658 | 90 mg hydrocortisone acetate suppository with Sephure suppository applicator | 3件: Acetate Acetate, Hydrocortisone, Hydrocortisone acetate | 2件: D00088
D00088
,
D00165
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
659 | 90 mg idrocortisone acetato in supposta con appli | - | - | - | - | 1件: 97 97 |
660 | 90 mg idrocortisone acetato in supposta con applicatore per supposte Sephure | - | - | - | - | 1件: 97 97 |
661 | 90 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
662 | 9060X | - | - | - | - | 2件: 13 13, 149 |
663 | 95% Pure ECGC capsules 200mg | - | - | - | - | 1件: 13 13 |
664 | 9512 | - | - | - | - | 1件: 46 46 |
665 | 9715X | - | - | - | - | 1件: 90 90 |
666 | 9741X | - | - | - | - | 1件: 90 90 |
667 | 9742X | - | - | - | - | 1件: 90 90 |
668 | 98% dehydrated alcohol | 1件: Ethanol Ethanol | 4件: D00068
D00068
,
D02798
,
D04855
,
D06542
| - | - | 1件: 298 298 |
669 | 98-92-0 | - | - | - | - | 1件: 107 107 |
670 | 980nm laser | - | - | - | - | 1件: 34 34 |
671 | 99m technetium infliximab | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 84 84 |
672 | 99mTc-3PRGD2 | - | - | - | - | 1件: 46 46 |
673 | 99mTc-Infliximab | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 84 84 |
674 | 99mTc-rhAnnexin V-128 | - | - | - | - | 2件: 46 46, 271 |
675 | 99mTc-S-HYNIC Certolizumab pegol | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 |
676 | : 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-N- | - | - | - | - | 1件: 86 86 |
677 | : immunoglobulina umana normale 10% per somministrazione endovenosa | - | - | - | - | 1件: 14 14 |
678 | ?-3 polyunsaturated fatty acid | - | - | - | - | 1件: 96 96 |
679 | [11C]-GSK2256098 500 MBq | 1件: GSK2256098 GSK2256098 | - | - | - | 1件: 86 86 |
680 | [11C]-PIB | - | - | - | - | 1件: 6 6 |
681 | [11C]CPPC Injection | - | - | - | - | 1件: 2 2 |
682 | [11C]MPC6827 | - | - | - | - | 1件: 2 2 |
683 | [11C]PXT012253 | - | - | - | - | 1件: 6 6 |
684 | [123I] 5-IA | - | - | - | - | 1件: 6 6 |
685 | [123I] IBVM and SPECT imaging | - | - | - | - | 1件: 6 6 |
686 | [123I] mZINT injection and serial dynamic SPECT imaging | - | - | - | - | 1件: 6 6 |
687 | [123I]-IBVM | - | - | - | - | 1件: 6 6 |
688 | [123I]-IBZM imaging | - | - | - | - | 1件: 6 6 |
689 | [123I]B-CIT | - | - | - | - | 1件: 6 6 |
690 | [123I]B-CIT SPECT imaging | - | - | - | - | 1件: 6 6 |
691 | [123I]beta CIT | - | - | - | - | 1件: 6 6 |
692 | [123I]beta CIT and SPECT imaging | - | - | - | - | 1件: 6 6 |
693 | [123I]beta-CIT | - | - | - | - | 1件: 6 6 |
694 | [123I]beta-CIT and SPECT imaging | - | - | - | - | 1件: 6 6 |
695 | [123I]CLINDE | - | - | - | - | 2件: 6 6, 13 |
696 | [123I]MNI-420 | - | - | - | - | 2件: 6 6, 8 |
697 | [123I]ß CIT | - | - | - | - | 1件: 6 6 |
698 | [123I]ß CIT and SPECT imaging | - | - | - | - | 1件: 6 6 |
699 | [123I]ß-CIT | - | - | - | - | 1件: 6 6 |
700 | [123I]ß-CIT and SPECT imaging | - | - | - | - | 1件: 6 6 |
701 | [124I]IB PF 06687234 | - | - | - | - | 2件: 96 96, 97 |
702 | [14C] AT1001 | - | - | - | - | 1件: 19 19 |
703 | [14C]-BIA 9-1067 | 1件: BIA BIA | - | - | - | 1件: 6 6 |
704 | [18F] APN-1607 | - | - | - | - | 1件: 5 5 |
705 | [18F] CFPyPB | - | - | - | - | 1件: 6 6 |
706 | [18F] FES | - | - | - | - | 1件: 86 86 |
707 | [18F] GE-180 | - | - | - | - | 1件: 2 2 |
708 | [18F] LBT-999 PET | - | - | - | - | 1件: 6 6 |
709 | [18F] PBR06 | - | - | - | - | 2件: 6 6, 13 |
710 | [18F] PI-2620 | - | - | - | - | 1件: 6 6 |
711 | [18F]-FBA-A20FMDV2 | - | - | - | - | 1件: 85 85 |
712 | [18F]-FEPPA | - | - | - | - | 2件: 6 6, 13 |
713 | [18F]-FLT-PET/CT scans | - | - | - | - | 1件: 34 34 |
714 | [18F]-PI2620 | - | - | - | - | 1件: 5 5 |
715 | [18F]DPA-714 PET | - | - | - | - | 1件: 2 2 |
716 | [18F]DPA-714 PET scan | - | - | - | - | 1件: 6 6 |
717 | [18F]FDOPA | - | - | - | - | 2件: 6 6, 17 |
718 | [18F]FDOPA PET/CT | - | - | - | - | 1件: 6 6 |
719 | [18F]Florbetaben | - | - | - | - | 1件: 28 28 |
720 | [18F]Florbetapir | - | - | - | - | 1件: 5 5 |
721 | [18F]Florbetapir PET imaging | - | - | - | - | 1件: 13 13 |
722 | [18F]flumazenil | 1件: Flumazenil Flumazenil | 1件: D00697
D00697
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 206 206 |
723 | [18F]Fluoro-2-deoxy-2-D-glucose | 1件: D-glucose D-glucose | 1件: D00009
D00009
| - | - | 2件: 86 86, 88 |
724 | [18F]FP-R01-MG-F2 | - | - | - | - | 2件: 85 85, 94 |
725 | [18F]FPEB | - | - | - | - | 3件: 6 6, 8, 206 |
726 | [18F]FPEB PET imaging | - | - | - | - | 1件: 206 206 |
727 | [18F]FSPG | - | - | - | - | 2件: 96 96, 97 |
728 | [18F]MK-9470 | - | - | - | - | 1件: 6 6 |
729 | [18F]MNI-1126 | - | - | - | - | 1件: 6 6 |
730 | [18F]MNI-444 | - | - | - | - | 1件: 6 6 |
731 | [18F]MNI-815 (MNI-815) | - | - | - | - | 1件: 5 5 |
732 | [18F]MNI-952 | - | - | - | - | 1件: 5 5 |
733 | [18F]MNI-958 | - | - | - | - | 1件: 5 5 |
734 | [18F]MPPF | - | - | - | - | 1件: 6 6 |
735 | [18F]NOS | - | - | - | - | 1件: 6 6 |
736 | [18F]P17-059 | - | - | - | - | 1件: 6 6 |
737 | [18F]PBR06 | - | - | - | - | 1件: 2 2 |
738 | [18F]PI-2620 | - | - | - | - | 2件: 6 6, 127 |
739 | [18F]T807 ([18F]MNI-777) | - | - | - | - | 2件: 5 5, 6 |
740 | [18F]UCB-2897 | - | - | - | - | 1件: 6 6 |
741 | [21CFR640.30] Plasma from 18 - 25 year old volunteer donors | - | - | - | - | 1件: 6 6 |
742 | [64]Cu Macrin | - | - | - | - | 1件: 84 84 |
743 | [68Ga]CBP8 | - | - | - | - | 1件: 85 85 |
744 | [C-11]Methylreboxetine | - | - | - | - | 1件: 13 13 |
745 | [C-11]PBR28 | - | - | - | - | 1件: 13 13 |
746 | [C11]PK-1195 PET scan | - | - | - | - | 1件: 13 13 |
747 | [F-18] Fluorodopa Positron Emission Tomography | - | - | - | - | 1件: 6 6 |
748 | [F-18]PBR06 | - | - | - | - | 2件: 13 13, 17 |
749 | [F-18]SDM-8 | - | - | - | - | 1件: 13 13 |
750 | [F18]-FDDNP | - | - | - | - | 1件: 5 5 |
751 | [Zr-89]Oxine-labeled leukocytes PET/MR | 1件: Oxyquinoline Oxyquinoline | 1件: D05321
D05321
| - | - | 1件: 13 13 |
752 | LNP023 HYDROCHLORIDE SALT | - | - | - | - | 5件: 61 61, 62, 66, 109, 222 |
753 | ÁCIDO GADOBÉNICO | - | - | - | - | 1件: 96 96 |
754 | Ácido risedrónico | - | - | - | - | 1件: 274 274 |